The Animal Core will continue to provide investigators of each project with assistance in the conduct of research involving animals. The core will provide a focus of expertise that is germane to all projects and also efficiently utilize valuable resources. The core's PI, Dr. E. Keller has extensive experience with prostate cancer xenograft development and rodent models of prostate cancer including intratibial and intracardiac injection models. Dr. Keller will oversee the scientific direction of the core. The core's day-to-day activities will be overseen by Dr. Jill Keller, an American College of Laboratory Animal Medicine certified veterinarian. The Animal Core activities include: - Creating animal models to be used for the projects. For example, implantation of vertebrae of mice to create vossicle models will be performed by the Animal Core. - Assisting with animal experiments. Core personnel will coordinate and assist or instruct in the performance of standardized procedures such as intratibial and intracardiac injection, anesthesia, etc. Providing imaging capability for animal studies. The core will perform faxitron radiographs, bone densitometry (Dexa or pQCT), and bioluminescence. - Maintaining breeding colonies for various specialized mice as required for various projects. Specific genetically-modified mice will be maintained as required. - Development of new animal models of bone metastasis. Dr. J. Keller will test xenografts and cell lines derived from the Prostate SPORE for their ability to serve as models of skeletal metastasis.
Bone metastasis are a serious and frequent clinical complication of prostate cancer. This core will provide animal models to help identify mechanisms and targets to attack this important aspect of prostate cancer.
|Jung, Younghun; Wang, Jingcheng; Lee, Eunsohl et al. (2015) Annexin 2-CXCL12 interactions regulate metastatic cell targeting and growth in the bone marrow. Mol Cancer Res 13:197-207|
|Yumoto, Kenji; Berry, Janice E; Taichman, Russell S et al. (2014) A novel method for monitoring tumor proliferation in vivo using fluorescent dye DiD. Cytometry A 85:548-55|
|Yumoto, Kenji; Eber, Matthew R; Berry, Janice E et al. (2014) Molecular pathways: niches in metastatic dormancy. Clin Cancer Res 20:3384-9|
|Dai, Jinlu; Zhang, Honglai; Karatsinides, Andreas et al. (2014) Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin Cancer Res 20:617-30|
|Yang, Kimberline R; Mooney, Steven M; Zarif, Jelani C et al. (2014) Niche inheritance: a cooperative pathway to enhance cancer cell fitness through ecosystem engineering. J Cell Biochem 115:1478-85|
|Wan, Liling; Hu, Guohong; Wei, Yong et al. (2014) Genetic ablation of metadherin inhibits autochthonous prostate cancer progression and metastasis. Cancer Res 74:5336-47|
|Zhang, H; Yu, C; Dai, J et al. (2014) Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of *-catenin activation of the DKK1 promoter in prostate cancer. Oncogene 33:2464-77|
|Soki, Fabiana N; Koh, Amy J; Jones, Jacqueline D et al. (2014) Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis. J Biol Chem 289:24560-72|
|Deng, Xiyun; He, Guangchun; Liu, Junwen et al. (2014) Recent advances in bone-targeted therapies of metastatic prostate cancer. Cancer Treat Rev 40:730-8|
|Roca, Hernan; Pande, Manjusha; Huo, Jeffrey S et al. (2014) A bioinformatics approach reveals novel interactions of the OVOL transcription factors in the regulation of epithelial - mesenchymal cell reprogramming and cancer progression. BMC Syst Biol 8:29|
Showing the most recent 10 out of 137 publications